ELVN
Price:
$24.54
Market Cap:
$1.20B
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.[Read more]
Industry
Biotechnology
IPO Date
2020-03-12
Stock Exchange
NASDAQ
Ticker
ELVN
According to Enliven Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 17.44. This represents a change of 25.52% compared to the average of 13.90 of the last 4 quarters.
The mean historical Current Ratio of Enliven Therapeutics, Inc. over the last ten years is 21.39. The current 17.44 Current Ratio has changed 8.05% with respect to the historical average. Over the past ten years (40 quarters), ELVN's Current Ratio was at its highest in in the December 2022 quarter at 48.98. The Current Ratio was at its lowest in in the March 2019 quarter at 0.
Average
21.39
Median
10.28
Minimum
4.21
Maximum
88.35
Discovering the peaks and valleys of Enliven Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.11%
Maximum Annual Current Ratio = 88.35
Minimum Annual Increase = -78.23%
Minimum Annual Current Ratio = 4.21
Year | Current Ratio | Change |
---|---|---|
2023 | 10.28 | 28.43% |
2022 | 8.00 | -58.40% |
2021 | 19.24 | -78.23% |
2020 | 88.35 | 1.11% |
2019 | 7.29 | 73.45% |
2018 | 4.21 | -66.02% |
The current Current Ratio of Enliven Therapeutics, Inc. (ELVN) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
12.51
5-year avg
26.63
10-year avg
21.39
Enliven Therapeutics, Inc.’s Current Ratio is less than Theseus Pharmaceuticals, Inc. (29.93), greater than PMV Pharmaceuticals, Inc. (13.98), less than Cullinan Oncology, Inc. (24.46), greater than Immuneering Corporation (7.99), greater than Aerovate Therapeutics, Inc. (8.78), less than MoonLake Immunotherapeutics (25.51), less than Structure Therapeutics Inc. (27.63), less than Compass Therapeutics, Inc. (40.74), greater than Replimune Group, Inc. (10.11), greater than Nuvectis Pharma, Inc. (2.74), greater than Lyra Therapeutics, Inc. (3.64), greater than Kronos Bio, Inc. (8.32), greater than Gossamer Bio, Inc. (6.74), less than Eliem Therapeutics, Inc. (60.41), greater than Inhibrx Biosciences, Inc. (4.70), greater than Merrimack Pharmaceuticals, Inc. (10.78), greater than Celcuity Inc. (10.36),
Company | Current Ratio | Market cap |
---|---|---|
29.93 | $181.50M | |
13.98 | $83.31M | |
24.46 | $730.17M | |
7.99 | $65.21M | |
8.78 | $76.81M | |
25.51 | $3.43B | |
27.63 | $1.91B | |
40.74 | $205.01M | |
10.11 | $1.02B | |
2.74 | $98.54M | |
3.64 | $12.37M | |
8.32 | $54.49M | |
6.74 | $157.63M | |
60.41 | $342.68M | |
4.70 | $203.82M | |
10.78 | $223.97M | |
10.36 | $489.74M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Enliven Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Enliven Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Enliven Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for Enliven Therapeutics, Inc. (ELVN)?
What is the highest Current Ratio for Enliven Therapeutics, Inc. (ELVN)?
What is the 3-year average Current Ratio for Enliven Therapeutics, Inc. (ELVN)?
What is the 5-year average Current Ratio for Enliven Therapeutics, Inc. (ELVN)?
How does the current Current Ratio for Enliven Therapeutics, Inc. (ELVN) compare to its historical average?